BioCentury
ARTICLE | Financial News

Gamida raises $40M in series F round

June 19, 2017 11:41 PM UTC

Cell therapy company Gamida Cell Ltd. (Jerusalem, Israel) raised $40 million in a series F round led by Shavit Capital. New investors VMS Investment Group and Israel Biotech Fund participated, as did existing investors Novartis AG (NYSE:NVS; SIX:NOVN), Clal Biotechnology Industries and Israel HealthCare Ventures.

Gamida's NiCord, an enriched cord blood product for use in bone marrow transplantation, is in a Phase III study to treat hematological malignancies. NiCord comprises ex vivo nicotinamide-expanded hematopoietic stem and progenitor cells derived from umbilical cord blood...

BCIQ Company Profiles

Gamida Cell Ltd.